|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although MAGEA1's expression levels have been evaluated as one of the cancer testis (CT) antigens for immunotherapy in melanoma and several other cancers, its functional role and signaling mechanisms are largely unknown.
|
28459460 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells.
|
26640592 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
There has been an explosion in CTA-based research since CTAs were first identified in 1991 and MAGE-1 was shown to elicit an autologous cytotoxic T-lymphocyte (CTL) response in a patient with melanoma.
|
22710665 |
2012 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Detecting MAGE-1, SSX-1 and CTp11 mRNA in PBMC improves the total diagnostic rate of HCC.
|
20731022 |
2010 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of the study was to identify whether melanoma antigen (MAGE)-1 mRNA and alpha-fetoprotein (AFP) mRNA expressed in peripheral blood could be used to predict the recurrence and metastasis of hepatocellular carcinoma (HCC) after hepatectomy.
|
19183381 |
2009 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells.
|
16497664 |
2006 |
|
Liver carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
LHGDN |
5' CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC.
|
16516880 |
2006 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical grade DC from melanoma patients were generated from blood monocytes and infected with a recombinant ALVAC virus encoding either a marker gene (EGFP) or the MAGE-1-MAGE-3 minigenes.
|
15665821 |
2005 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although MAGE-1 expression has been considered as a target for immunomodulation therapy, our findings do not indicate consistent expression of this epitope in a majority of melanomas.
|
15223957 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
In the present study, we analyzed the expression of MAGE-1 and -3 genes in the hepatocellular carcinoma (HCC) tissue as well as frequency, phenotype and function of circulating and tumor infiltrating CD8+ cells specific for HLA-A1 and -A2 restricted epitopes of MAGE-1 and -3.
|
14672620 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the expression of cancer-testis (CT) antigens MAGE-1, SSX-1,CTp11 and HCA587 genes in hepatocellular carcinoma (HCC) and the possibility of applying these antigens as targets for specific immunotherapy for HCC.
|
15237429 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we analyzed the expression of MAGE-1 and -3 genes in the hepatocellular carcinoma (HCC) tissue as well as frequency, phenotype and function of circulating and tumor infiltrating CD8+ cells specific for HLA-A1 and -A2 restricted epitopes of MAGE-1 and -3.
|
14672620 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peripheral blood mononuclear cells from the HCC patient pulsed with an MAGE-1 peptide (NYKCRFPEI) were used as antigen presenting cells.
|
12150730 |
2002 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MAGE-1 and/or MAGE-3 mRNA were not detected in the PBMC of those patients from whom the resected HCC tissues were MAGE-1 or MAGE-3 mRNA negative, nor in the 25 PBMC samples from healthy donors.
|
11857021 |
2002 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subsequently, we chose four sets of primers for the melanoma-associated antigens MAGE1, tyrosinase, Melan A/MART-1 and gp100/Pmel17 and performed PCR analysis over a range of cycle numbers.
|
11604998 |
2001 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using several different preexisting tumor models that make use of B16F10 melanoma cells expressing a target tumor antigen (human melanoma-associated gene [MAGE]-1), we found that vaccination with bone marrow-derived DCs engineered to express MAGE-1 via adenoviral-mediated gene transfer led to a dramatic decrease in the number of metastases in a lung metastasis model, and led to prolonged survival and some long-term cures in a subcutaneous preexisting tumor model.
|
10811863 |
2000 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peptide sequences from MAGE-1, 2, 3, 4a, and 6 aligned to MAGE-12:170-178 were not recognized by F001-TIL.
|
10754339 |
2000 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The MAGE-1 expression was detected in 69% of biopsied HCC samples and the expression was high in both small and well-differentiated HCC.
|
10782910 |
2000 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study shows that MAGE-1 mRNA is highly expressed in HCC tumor tissue in Chinese patients.
|
11776148 |
2000 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Knowledge of these mechanisms led to the design of a non-natural, minimally modified analogue of MAGE-1.A1, [Aib2, NMe-Ser8]MAGE-1.A1, which was highly peptidase-resistant and bound to MHC and activated MAGE-1.A1-specific anti-melanoma CTLs.
|
10187808 |
1999 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of MAGE-10 in melanoma tumors was found to parallel that of MAGE-1.
|
10446460 |
1999 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MAGE 1 and 3 gene expression was also not detected in any of the cases of benign and dysplastic melanocytic naevi and in situ MMs.
|
10215777 |
1999 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Transcription of the MAGE-1 gene and the methylation status of its Ets binding promoter elements: a quantitative analysis in melanoma cell lines using a real-time polymerase chain reaction technique.
|
10465576 |
1999 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that the detection of the genes by RT-PCR or the proteins by Western blotting is useful for differentiating early HCCs from non-cancerous lesions, and that the peptides derived from MAGE-1 and -3 proteins might be suitable targets for immunotherapy of human HCC.
|
10576668 |
1999 |